The present invention relates generally to polymer blends for fabricating films and more particularly film that have low distortion, that are non-adherent upon steam sterilization, that are radio-frequency sealable, and that are suitable for fabricating into flexible medical containers.
In the medical field, where beneficial agents are collected, processed and stored in containers, transported, and ultimately delivered through tubes by infusion to patients to achieve therapeutic effects, materials which are used to fabricate the containers must have a unique combination of properties. For example, in order to visually inspect solutions for particulate contaminants, the container must be optically transparent. To infuse a solution from a container by collapsing the container walls, without introducing air into the container, the material which forms the walls must be sufficiently flexible. The material must be functional over a wide range of temperatures. The material must function at low temperatures by maintaining its flexibility and toughness because some solutions, for example, certain pre-mixed drug solutions are stored and transported in containers at temperatures such as −25° C. to −30° C. to minimize the drug degradation. The material must also be functional at high temperatures to withstand the heat of sterilization; a process which most medical packages and nutritional products are subjected to prior to shipment. The sterilization process usually includes exposing the container to steam at temperatures typically 121° C. and at elevated pressures. Thus, the material needs to withstand the temperature and pressures without significant distortions (“heat distortion resistance”).
For ease of manufacture into useful articles, it is desirable that the material be sealable using radio frequency (“RF”) generally at about 27.12 MHZ. Therefore, the material should possess sufficient dielectric loss properties to convert the RF energy to thermal energy. A further requirement is to minimize the environmental impact upon the disposal of the article fabricated from the material after its intended use. For those articles that are disposed of in landfills, it is desirable to use as little material as possible and avoid the incorporation of low molecular weight leachable components to construct the article. Thus, the material should be light weight and have good mechanical strength. Further benefits are realized by using a material which may be recycled by thermoplastically reprocessing the post-consumer article into other useful articles.
For those containers that are disposed of through incineration, it is necessary to use a material that helps to eliminate the dangers of biological hazards, and to minimize or eliminate entirely the formation of inorganic acids which are environmentally harmful, irritating, and corrosive, or other products which are harmful, irritating, or otherwise objectionable upon incineration.
It is also desirable that the material be free from or have a low content of low molecular weight additives such as plasticizers, stabilizers and the like which could be released into the medications or biological fluids or tissues thereby causing danger to patients using such devices or are contaminating such substances being stored or processed in such devices. For containers which hold solutions for transfusion, such contamination could make its way into the transfusion pathway and into the patient causing injury or death to the patient.
Traditional flexible polyvinyl chloride materials meets a number of, and in some cases, most of the above-mentioned requirements. Polyvinyl chloride (“PVC”) also offers the distinct advantage of being one of the most cost effective materials for constructing devices which meet the above requirements. However, PVC may generate objectionable amounts of hydrogen chloride (or hydrochloric acid when contacted with water) upon incineration, causing corrosion of the incinerator. PVC sometimes contains plasticizers which may leach into drugs or biological fluids or tissues that come in contact with PVC formulations. Thus, many materials have been devised to replace PVC. However, most alternate materials are too expensive to implement and still do not meet all of the above requirements.
There have been many attempts to develop a film material to replace PVC, but most attempts have been unsuccessful for one reason or another. For example, in U.S. Pat. No. 4,966,795, which discloses multilayer film compositions capable of withstanding the steam sterilization, cannot be welded by radio frequency dielectric heating thus cannot be assembled by this rapid, low costs, reliable and practical process. European Application No. EP 0 310 143 A1 discloses multilayer films that meet most of the requirements, and can be RF welded. However, components of the disclosed film are cross-linked by radiation and, therefore, cannot be recycled by the standard thermoplastic processing methods. In addition, due to the irradiation step, appreciable amounts of acetic acid is liberated and trapped in the material. Upon steam sterilization, the acetic acid migrates into the packaging contents as a contaminant and by altering the pH of the contents acts as a potential chemical reactant to the contents or as a catalyst to the degradation of the contents.
U.S. Pat. No. 5,998,019, which is owned by the same assignee of the present invention, discloses multi-layered polymer structures that solve many, if not all, of the foregoing problems. However, one problem with the structures of the '019 patent is that the internal solution contact layer of those structures sticks to either itself or to other similar structures (such as other films or when formed into a container) after the autoclave sterilization process. The internal solution contact layer of the '019 patent is either an RF sealable layer or a blend of two polyolefins and a compatibilizing agent of a styrene and hydrocarbon block copolymer. The specific composition of the RF sealable layer is disclosed therein and is also the subject of U.S. Pat. Nos. 5,849,843; 5,854,347 and 5,686,527, which are owned by the present assignee and are incorporated by reference.
U.S. Pat. No. 6,083,587, also owned by the present assignee, provides a multilayer structure where the internal solution contact layer can be a polyolefin selected from the homopolymers and copolymers of alpha-olefins having about 2 to about 20 carbons. However, the '587 patent does not disclose a structure wherein an internal, non-solution contact layer is RF sealable layer or comprised of an RF susceptible polymer.
The main objective of the present invention is the creation of thermoplastic materials which are, overall, superior to those materials, of which we are aware, which have been heretofore known to the art or have been commercially used or marketed. The properties of such materials includes flexibility, extensibility, and strain recoverability, not just at room temperatures, but through a wide range of ambient and refrigerated temperatures. The material should be sufficiently optically transparent for visual inspection, and steam sterilizable at temperatures up to 121° C. The material should be capable of being subjected to significant strains without exhibiting strain whitening, which can indicate a physical and a cosmetic defect. A further objective is that the material be capable of assembly by the RF methods.
Another objective is that the material be substantially free of low molecular weight leachable additives, and be capable of safe disposal by incineration without the generation of significant amounts of corrosive inorganic acids. Another objective is that the material be recyclable by standard thermoplastic processing methods after use. It is also desirable that the material incorporate reground scrap material recovered during the manufacturing process to save material costs and reduce manufacturing waste. It is also desirable that the material not have its RF sealable layer able to contact itself of that of another film, minimizing the film from sticking to itself or to other films during, or subsequent to, the autoclave process. It is also desirable that the material not be oriented, as oriented films may shrink when subjected to heat. Finally, the material should serve as a cost effective alternative to various PVC formulations currently being used for medical devices.
When more than one polymer is blended to form an alloying composition, it is difficult to achieve all of the above objectives simultaneously. For example, in most instances alloy composition may scatter light; thus, they fail to meet the optical clarity objective. The light scattering intensity (measured by haze) depends on the domain size of components in the micrometer (μm) range, and the proximity of the refractive indices of the components. As a general rule, the selection of components that can be satisfactorily processed into very small domain sizes, and yet with a minimum of refractive index mismatches, is a difficult task. Also, film structures heretofore known usually contain stearates or fatty acids in the solution-contact layer of the structure, thereby permitting those undesirable components to leach into the solution in contact with the film structure.
The present invention is provided to solve these and other problems.
In accordance with the present invention, certain multiple layer polymer based structures are disclosed. The films may be fabricated into medical grade articles such as containers for storing medical solutions or blood products, blood bags, and related items, or other products constructed from multi-layered structures.
It is an object of the present invention to prepare a multi-layered film having the following physical properties: (1) a mechanical modulus less than 40,000 psi and more preferably less than 25,000 psi when measured in accordance with ASTM D-882, (2) a greater than or equal to 70%, and more preferably greater than or equal to 75%, recovery in length after an initial deformation of 20%, (3) and optical haze of less than 30%, and more preferably less than 15%, when measured for a composition 9 mils thick and in accordance to ASTM D-1003, (4) a loss tangent measured at 1 Hz at processing temperatures is greater than 1.0, and more preferably greater than 2.0, (5) the content of elemental halogens is less than 0.1%, and more preferably less than 0.01%, (6) the low molecular weight water soluble fraction is less than 0.1%, and more preferably less than 0.005%, (7) the maximum dielectric loss between 1 and 60 MHZ and between the temperature range of 25° C. to 250° C. is greater than or equal to 0.05 and more preferably greater than or equal to 0.1, (8) autoclave resistance measured by sample creep at 121° C. under 27 psi loading is less than or equal to 60% and more preferably less than or equal to 20%, and (9) there is no strain whitening after being strained at moderate speeds of about 20 inches (50 cm) per minute at about 100% elongation and the presence of strain whitening is noted or the lack thereof.
The multiple layer structure of the present invention has two separate skin layers, each preferably containing a propylene containing polymer. The structure further includes a radio frequency (“RF”) susceptible layer adhered to the skin layer. The RF layer is composed of a first component of a polypropylene polymer, a second component of a non propylene polyolefin (one that does not contain propylene repeating units), a third component of a radio frequency susceptible polymer, and a fourth component of a polymeric compatibilizing agent. In alternate embodiments, additional layers such as core, scrap, and barrier layers are added to the skin and RF layers to confer additional or enhanced functionality of the resultant film structure.
As stated above, the RF layer is the subject of U.S. Pat. Nos. 5,849,843; 5,854,347 and 5,686,527, which are incorporated herein by reference and made a part hereof. The multi-layered film structure of the present invention offers additional features that the compositions of the RF layer alone do not provide. The additional features of the multi-layer film include an exterior surface gloss and reduced tackiness to the outside surface of the film structure. Additionally, the multilayered film structure has improved vapor barrier properties, greater strength and optical clarity, and is cleaner or has reduced tendency to migrate into the contents of the container. Finally, the internal solution contact layer of the present invention minimizes partial and total sticking of that layer to itself or other films during, and subsequent to, the autoclave process.
The core layer, which is interposed between the skin layer and the RF layer consists of three components. Preferably, the first component is polypropylene which constitutes about 40% of the core layer, the second component is an ultra low density polyethylene (“ULDPE”) which constitutes about 50% by weight of the core layer, and the third component is styrene-hydrocarbon block copolymer and more preferably an SEBS block copolymer which constitutes about 10% by weight of the core layer. The entire core layer should be about 4.0 mils thick.
It is also desirable, for economic reasons among others, to incorporate reground scrap material recovered during the processing of the film material back into the composition of a film structure. This can lead to using significant amount of scrap material as a weight percent of the entire layer structure, thereby substantially decreasing the costs of the film product. The reground scrap may be incorporated into the above-described structure either as an additional discrete layer located somewhere between the skin layer and the RF layer or may be blended into the core layer as an additional component. In either case, significant resources are saved by reprocessing the scrap material.
To increase gas barrier properties of the structure, it is desirable to incorporate a barrier layer between the skin layer and the RF layer. The barrier layer may be attached to surrounding layers using adhesive tie layers. The barrier layer may be selected from ethylene vinyl alcohols such as that sold under the name Evalca (Evalca Co.), highly glassy or crystalline polyamide such as Sclar PA® (Dupont Chemical Co.), high nitrile content acrylonitrile copolymers such as those sold under the tradename Barex® sold by British Petroleum.
Films having the aforesaid structure and compositions have been found to be flexible, optically clear, non-strain whitening, and steam and radiation sterilizable. Additionally, the films are compatible with medical applications because the components that constitute the film have a minimal extractability to the fluids and contents with which the composition comes into contact. Further, the films are environmentally sound in that they do not generate harmful degradants upon incineration. Finally, the films provide a cost effective alternative to PVC.
Additional features and advantages of the present invention are described in, and will be apparent from, the drawing and the detailed description of the presently preferred embodiments.
While this invention is susceptible of embodiments in many different forms, and will herein be described in detail, preferred embodiments of the invention are disclosed with the understanding that the present disclosure is to be considered as exemplifications of the principles of the invention and are not intended to limit the broad aspects of the invention to the embodiments illustrated.
According to the present invention, multiple layered film structures are provided which meet the requirements set forth above.
The first skin layer and the second skin layer each preferably are a propylene-containing polymer. Suitable propylene-containing polymers include those selected from the group consisting of homopolymers of polypropylene, copolymers and terpolymers of propylene with one or more comonomers selected from α-olefins having from 2 to about 18 carbons. Suitable polypropylene copolymers and terpolymers include random or block propylene and ethylene copolymers or random or block propylene/ethylene/butene terpolymers. Suitable propylene and α-olefin copolymers are sold by Montell under the tradenames PRO FAX, PRO FAX ULTRA and CATALLOY and by Fina Oil & Chemical Company (n/k/a ATOFINA) under the Fina® tradename series, such as Fina 6671 XBB, 6573 XHC, 7450 HC, and 7602 Z. The first skin layer 12 and the second skin layer 14 should have a thickness within the range of from about 0.2 to about 3.0 mils thick. Both skin layers may further include a second component of a styrene and hydrocarbon copolymer, more preferable a styrene and hydrocarbon block copolymer and even more preferably a styro-ethylene butene styrene tri-block copolymer SEBS, which is commercially available from the Shell Chemical Company/Ripplewood Holdings LLC under the tradename KRATON™ product series. More preferably, the SEBS component is KRATON™ G-1657.
The RF susceptible layer 16 of the present invention should have a dielectric loss of greater than 0.05 at frequencies within the range of 1-60 MHz within a temperature range of ambient to 250° C. The RF layer 16 preferably has four components. The RF layer 16 confers RF sealability, flexibility, heat distortion resistance, and compatibility to the film structure 10. The first component of the RF layer 16 is chosen from polypropylene copolymers and preferably the propylene alpha-olefin random copolymers (“PPE”). The PPE's possess the required rigidity and the resistance to yielding at the autoclave temperatures of about 121° C. However, by themselves, the PPE's are too rigid to meet the flexibility requirements. When combined by alloying with certain low modulus polymers, good flexibility can be achieved.
These low modulus copolymers can include ethylene based copolymers such as ethylene-co-vinyl acetate (“EVA”), ethylene co-alpha olefins, or the so-called ultra low density (typically less than 0.90 Kg/L) polyethylenes (“ULDPE”). These ULDPE include those commercially available products sold under the trademarks TAFMER® (Mitsui Petrochemical Co.) under the product designation A485, Exact® (Exxon Chemical Company) under the product designations 4023-4024, and Insite® technology polymers (Dow Chemical Co.). In addition, polybutene-1 (“PB”), such as those sold by Shell Chemical Company under product designations PB-8010, PB-8310; thermoplastic elastomers based on SEBS block copolymers, (Shell Chemical Company), poly isobutene (“PIB”) under the product designations Vistanex L-80, L-100, L-120, L-140 (Exxon Chemical Company), ethylene alkyl acrylate, the methyl acrylate copolymers (“EMA”) such as those under the product designation EMAC 2707, and DS-1130 (Chevron), and n-butyl acrylates (“ENBA”) (Quantum Chemical) were found to be acceptable copolymers. Ethylene copolymers such as the acrylic and methacrylic acid copolymers and their partially neutralized salts and ionomers, such as PRIMACOR® (Dow Chemical Company) and SURYLN® (E.I. DuPont de Nemours & Company) were also acceptable. Typically, ethylene based copolymers have melting point temperatures of less than about 110° C. are not suited for autoclaving at 121° C. applications. Furthermore, only a limited range of proportions of each component allows the simultaneous fulfillment of the flexibility and autoclavability requirements.
Preferably the first component is chosen from the group of polypropylene homo and random copolymers with alpha olefins. The first component constitutes approximately 30-60%, more preferably 35-45%, and most preferably 45%, by weight of the RF layer. For example, a preferred first component comprises random copolymers of propylene and ethylene where the ethylene content is in an amount within the range of 0-6%, and more preferably from about 2% to about 6% by weight of the copolymer.
The second component of the RF layer 16 confers flexibility and low temperature ductility to the RF layer 16 and is chosen from the group consisting of polyolefins that do not have propylene repeating units (“non-propylene based polyolefins”) including ethylene copolymers including ULDPE, polybutene, butene ethylene copolymers, ethylene vinyl acetate copolymers with vinyl acetate contents between approximately 18-50%, ethylene methyl acrylate copolymers with methyl acrylate contents being between approximately 20-40%, ethylene n-butyl acrylate copolymers with n-butyl acrylate content of between 20-40%, ethylene acrylic acid copolymers with the acrylic acid content of greater than approximately 15%. An example of these products are sold under such product designations as Tafmer A-4085 (Mitsui), EMAC DS-1130 (Chevron), Exact 4023, 4024 and 4028 (Exxon). Preferably, the second component is either ULDPE sold by Mitsui Petrochemical Company under the designation TAFMER A-4085, or polybutene-1, PB8010 and PB8310 (Shell Chemical Co.), and should constitute approximately 25-50%, more preferably 35-45%, and most preferably 45%, by weight of the film.
The first and second components of the RF layer 16 may be replaced by a single component selected from a high melting temperature and flexible olefins such as those polypropylenes sold by the Rexene Company under the product designation FPO. The melting point temperature of this component should be greater than 130° C. and the modulus less than 20,000 psi. This component should constitute between 30-60% by weight of the RF layer.
To impart RF dielectric loss to the RF layer 16, certain known high dielectric loss ingredients are included as the third component of the film structure 10. For example, EVA and EMA of sufficiently high co-monomer contents exhibit significant loss properties at 27 MHZ to allow the compositions to be sealed by the dielectric process. Polyamides as a class of material, and ethylene vinyl alcohol (“EVOH”) copolymers (typically produced by hydrolysing EVA copolymers), both possess high dielectric loss properties at suitable temperatures. Other active materials include PVC, vinylidine chlorides, and fluorides, copolymer of bis-phenol-A and epichlorohydrines known as PHENOXYS® (Union Carbide). However, significant contents of these chlorine and fluorine containing polymers would make them environmentally unsound as incineration of such a material would generate inorganic acids. Therefore, the third component of the RF layer 16 is preferably chosen from the class of polyamides.
Preferably, the polyamides of the present invention will be chosen from aliphatic polyamides resulting from the condensation reaction of di-amines having a carbon number within a range of 2-13, aliphatic polyamides resulting from a condensation reaction of di-acids having a carbon number within a range of 2-13, polyamides resulting from the condensation reaction of dimer fatty acids, and amide containing copolymers (random, block or graft).
Polyamides such as nylons are widely used in film material because they offer abrasion resistance to the film. However, rarely are the nylons found in the layer that contacts medical solutions as they typically contaminate the solution by leaching out into the solution. However, it has been found by the applicants of the present invention that various dimer fatty acid polyamides sold by, for example, Henkel Corporation under the product designations MACROMELT and VERSAMID do not lead to such contamination and thus are the most preferred third component of the RF layer 16. The third component should constitute approximately 3-40%, more preferably between 7-13%, and most preferably 10%, by weight of the RF layer 16.
The fourth component of the RF layer 16 confers compatibility between the polar and nonpolar components of the RF layer 16. The fourth component was chosen from styrene-hydrocarbon block copolymers and preferably SEBS block copolymers that are modified by maleic anhydride, epoxy, or carboxylate functionalities. Most preferably the fourth component is an SEBS block copolymer that is maleic anhydride functionalized. Such a product is sold by Shell Chemical Company/Ripplewood Holdings LLC under product designation KRATON™ RP-6509. The fourth component should constitute approximately 5-40%, more preferably 7-13%, and most preferably 10% by weight of the RF layer 16.
It may also be desirable to include a fifth component to the RF layer 16 of an SEBS block copolymer, not modified by the above functional groups, such as the one sold by the Shell Chemical Company/Ripplewood Holdings LLC under the product designation KRATON™ G-1652. This component should constitute between 5-40% by weight of the RF layer 16, more preferably between 7-13%, and most preferably 10%.
Preferably the RF susceptible layer 16 will have a thickness within the range of 1-15 mils are more preferably 5.0 mils-8.0 mils, and most preferably 6.0 mils. The skin layer will have a thickness within the range of 0.2-3.0 mils and most preferably 0.5 mils.
The second component of the core layer 18 is chosen from a group consisting of compounds that confer flexibility to the core layer 18 including ULDPE, polybutene copolymers. Preferably, the second component of the core layer is ULDPE or polybutene-1 in an amount by weight of from about 40% to about 60%, more preferably from about 40 to about 50%, and most preferably 40%.
The third component of the core layer 18 is chosen from a group of compounds that confer compatibility among the components of the core layer 18 and includes styrene-hydrocarbon block copolymers and most preferably SEBS block copolymers. The third component is in an amount preferably within a range of from about 5 to about 40% by weight of the core layer 18, more preferably from about 7 to about 15%, and most preferably 15%.
It is also possible to add as a fourth component of the core layer 18, reground trim scrap material recovered during the manufacturing of containers. The scrap material is dispersed throughout the core layer 18. Scrap may be added in an amount preferably between approximately from about 0 to about 50% by weight of the core layer 18, and more preferably within the range of from about 10 to about 30% and most preferably within the range of from about 3 to about 12%. The present invention also contemplates any predetermined number of core layers (e.g., a second core layer) disposed in the multilayer film structure.
The barrier layer 22 increases the gas barrier properties of the film structure 10. The barrier layer 22 is selected from the group consisting ethylene vinyl alcohols such as that sold under the name Evalca (Evalca Co.), highly glassy or crystalline polyamide such as Sclar PA® (Dupont Chemical Co.), high nitrile content acrylonitrile copolymers such as Barex® sold by British Petroleum. Preferably, the barrier layer 22 is ethylene vinyl alcohol, and has a thickness within the range of 0.3-1.5 mils and most preferably 1.0 mils. The tie layers 24 may be selected from modified ethylene and propylene copolymers such as those sold under the product designations Prexar (Quantum Chemical Co.) and Bynel (Dupont) and should have a thickness within the range of 0.2-1.0 mils and most preferably 0.5 mil.
The above layers may be processed by coextrusion, extrusion coating, or other acceptable process. These materials may be used to manufacture I.V. therapy bags such as the one shown in FIG. 7 and generally designated as 50.
It is understood that the present invention is not limited to the particular examples described herein. The examples of Table 1 are proffered for the purpose of describing particular embodiments and are not intended to be limiting.
The above working examples, as well as other embodiments contemplated by the present invention, are believed to having the following properties measured in conformance with the experimental details the inventors disclosed in U.S. Pat. No. 6,261,655, which is incorporated by reference:
It will be understood that the invention may be embodied in other specific forms without departing from the spirit or central characteristics thereof. The present examples and embodiments, therefore, are to be considered in all respects as illustrative and not restrictive, and the invention is not to be limited to the details given herein.
This is a continuation-in-part application of U.S. patent application Ser. No. 09/498,674, which was filed on Feb. 7, 2000 U.S. Pat. No. 6,461,696; which is a continuation-in-part of U.S. patent application Ser. No. 09/334,957, which was filed on Jun. 17, 1999, and is now U.S. Pat. No. 6,261,655; which is a continuation of U.S. patent application Ser. No. 08/153,602 filed on Nov. 16, 1993, and is now U.S. Pat. No. 5,998,019, all of which are incorporated herein by reference and made a part hereof.
Number | Name | Date | Kind |
---|---|---|---|
2705223 | Renfrew et al. | Mar 1955 | A |
3255923 | Soto | Jun 1966 | A |
3375300 | Ropp | Mar 1968 | A |
3494897 | Reding et al. | Feb 1970 | A |
3514359 | Frese | May 1970 | A |
3536693 | Schrader et al. | Oct 1970 | A |
3772136 | Workman | Nov 1973 | A |
3912843 | Brazier | Oct 1975 | A |
3937758 | Castagna | Feb 1976 | A |
3955040 | Schirmer | May 1976 | A |
3995084 | Berger et al. | Nov 1976 | A |
4005710 | Zeddies et al. | Feb 1977 | A |
4041103 | Davison et al. | Aug 1977 | A |
4058647 | Inoue et al. | Nov 1977 | A |
4064296 | Bornstein et al. | Dec 1977 | A |
4082854 | Yamada et al. | Apr 1978 | A |
4082877 | Shadle | Apr 1978 | A |
4087587 | Shida et al. | May 1978 | A |
4087588 | Shida et al. | May 1978 | A |
4095012 | Schirmer | Jun 1978 | A |
4103686 | LeFevre | Aug 1978 | A |
4110303 | Gergen et al. | Aug 1978 | A |
4147827 | Breidt, Jr. et al. | Apr 1979 | A |
4197326 | Wakamatsu et al. | Apr 1980 | A |
4212956 | Katsura | Jul 1980 | A |
4212966 | McClain | Jul 1980 | A |
4220684 | Olson | Sep 1980 | A |
4230830 | Tanny et al. | Oct 1980 | A |
4233367 | Ticknor et al. | Nov 1980 | A |
4239826 | Knott, II et al. | Dec 1980 | A |
4244378 | Brignola | Jan 1981 | A |
4254169 | Schroeder | Mar 1981 | A |
4255490 | Katsura | Mar 1981 | A |
4281045 | Sumi et al. | Jul 1981 | A |
4284674 | Sheptak | Aug 1981 | A |
4286628 | Paradis et al. | Sep 1981 | A |
4310017 | Raines | Jan 1982 | A |
4311807 | McCullough, Jr. et al. | Jan 1982 | A |
4322465 | Webster | Mar 1982 | A |
4322480 | Tuller et al. | Mar 1982 | A |
4327726 | Kwong | May 1982 | A |
4332655 | Berejka | Jun 1982 | A |
4336352 | Sakurai et al. | Jun 1982 | A |
4349644 | Iwanami et al. | Sep 1982 | A |
4350797 | Marzola et al. | Sep 1982 | A |
4355721 | Knott, II et al. | Oct 1982 | A |
4361628 | Krueger et al. | Nov 1982 | A |
4369812 | Paradis et al. | Jan 1983 | A |
4387184 | Coquard et al. | Jun 1983 | A |
4397916 | Nagano | Aug 1983 | A |
4397917 | Chi et al. | Aug 1983 | A |
4405667 | Christensen et al. | Sep 1983 | A |
4407873 | Christensen et al. | Oct 1983 | A |
4407877 | Rasmussen | Oct 1983 | A |
4407888 | Crofts | Oct 1983 | A |
4417753 | Bacehowski et al. | Nov 1983 | A |
4429076 | Saito et al. | Jan 1984 | A |
4445550 | Davis et al. | May 1984 | A |
4457960 | Newsome | Jul 1984 | A |
4460632 | Adur et al. | Jul 1984 | A |
4464438 | Lu | Aug 1984 | A |
4465487 | Nakamura et al. | Aug 1984 | A |
4468427 | Degrassi et al. | Aug 1984 | A |
4479989 | Mahal | Oct 1984 | A |
4486497 | Mizutani | Dec 1984 | A |
4501798 | Koschak et al. | Feb 1985 | A |
4521437 | Storms | Jun 1985 | A |
4528219 | Yamada et al. | Jul 1985 | A |
4536409 | Farrell et al. | Aug 1985 | A |
4536532 | Miller et al. | Aug 1985 | A |
4548348 | Clements | Oct 1985 | A |
4551371 | Eckstein | Nov 1985 | A |
4552714 | Krueger et al. | Nov 1985 | A |
4552716 | Habich | Nov 1985 | A |
4552801 | Odorzynski et al. | Nov 1985 | A |
4561110 | Herbert | Dec 1985 | A |
4561920 | Foster | Dec 1985 | A |
4562118 | Maruhashi et al. | Dec 1985 | A |
4568333 | Sawyer et al. | Feb 1986 | A |
4568723 | Lu | Feb 1986 | A |
4572854 | Dallmann et al. | Feb 1986 | A |
4573994 | Fischell et al. | Mar 1986 | A |
4579784 | Lemstra et al. | Apr 1986 | A |
4588177 | White | May 1986 | A |
4588648 | Krueger et al. | May 1986 | A |
4590131 | Yazaki et al. | May 1986 | A |
4599276 | Martini | Jul 1986 | A |
4605576 | Jabarin | Aug 1986 | A |
4615922 | Newsome et al. | Oct 1986 | A |
4615926 | Hsu et al. | Oct 1986 | A |
4617240 | Krueger et al. | Oct 1986 | A |
4619849 | Anzawa et al. | Oct 1986 | A |
4627844 | Schmitt | Dec 1986 | A |
4628969 | Jurgens, Jr. et al. | Dec 1986 | A |
4636412 | Field | Jan 1987 | A |
4639398 | Bergström | Jan 1987 | A |
4640870 | Akazawa et al. | Feb 1987 | A |
4643926 | Mueller | Feb 1987 | A |
4645695 | Negi et al. | Feb 1987 | A |
4647483 | Tse et al. | Mar 1987 | A |
4650452 | Jensen | Mar 1987 | A |
4650721 | Ashcraft et al. | Mar 1987 | A |
4659903 | Berne et al. | Apr 1987 | A |
4668571 | Moriarty, Jr. | May 1987 | A |
4672087 | Miller et al. | Jun 1987 | A |
4677017 | DeAntonis et al. | Jun 1987 | A |
4683916 | Raines | Aug 1987 | A |
4684364 | Sawyer et al. | Aug 1987 | A |
4684573 | Mueller et al. | Aug 1987 | A |
4684576 | Tabor et al. | Aug 1987 | A |
4686125 | Johnston et al. | Aug 1987 | A |
4692361 | Johnston et al. | Sep 1987 | A |
4695491 | Kondo et al. | Sep 1987 | A |
4699816 | Galli | Oct 1987 | A |
4702966 | Farrell et al. | Oct 1987 | A |
4705708 | Briggs et al. | Nov 1987 | A |
4707389 | Ward | Nov 1987 | A |
4722725 | Sawyer et al. | Feb 1988 | A |
4724028 | Zabielski et al. | Feb 1988 | A |
4724185 | Shah | Feb 1988 | A |
4726984 | Shah | Feb 1988 | A |
4726997 | Mueller et al. | Feb 1988 | A |
4729476 | Lulham et al. | Mar 1988 | A |
4731266 | Bonnebat et al. | Mar 1988 | A |
4732795 | Ohya et al. | Mar 1988 | A |
4734327 | Vicik | Mar 1988 | A |
4735855 | Wofford et al. | Apr 1988 | A |
4740582 | Coquard et al. | Apr 1988 | A |
4746562 | Fant | May 1988 | A |
4753222 | Morishita | Jun 1988 | A |
4755419 | Shah | Jul 1988 | A |
4758463 | Vicik et al. | Jul 1988 | A |
4760114 | Haaf et al. | Jul 1988 | A |
4764404 | Genske et al. | Aug 1988 | A |
4767651 | Starczewski et al. | Aug 1988 | A |
4770944 | Farrell et al. | Sep 1988 | A |
4772497 | Maasola | Sep 1988 | A |
4778697 | Genske et al. | Oct 1988 | A |
4789575 | Gibbons et al. | Dec 1988 | A |
4792488 | Schirmer | Dec 1988 | A |
4795782 | Lutz et al. | Jan 1989 | A |
4800129 | Deak | Jan 1989 | A |
4803102 | Raniere et al. | Feb 1989 | A |
4808482 | Benge et al. | Feb 1989 | A |
4818592 | Ossian | Apr 1989 | A |
4826955 | Akkapeddi et al. | May 1989 | A |
4828915 | Schroeder et al. | May 1989 | A |
4834755 | Silvestrini et al. | May 1989 | A |
4839235 | Shah | Jun 1989 | A |
4842947 | Jachec et al. | Jun 1989 | A |
4855356 | Holub et al. | Aug 1989 | A |
4856259 | Woo et al. | Aug 1989 | A |
4856260 | Woo et al. | Aug 1989 | A |
4857399 | Vicik | Aug 1989 | A |
4857408 | Vicik | Aug 1989 | A |
4857409 | Hazelton et al. | Aug 1989 | A |
4863996 | Nakazima et al. | Sep 1989 | A |
4871410 | Bonnebat et al. | Oct 1989 | A |
4871799 | Kobayashi et al. | Oct 1989 | A |
4873287 | Holub et al. | Oct 1989 | A |
4875587 | Lulham et al. | Oct 1989 | A |
4877662 | Yazaki et al. | Oct 1989 | A |
4877682 | Sauers et al. | Oct 1989 | A |
4881649 | Hsu et al. | Nov 1989 | A |
4883696 | Iwanami et al. | Nov 1989 | A |
4883837 | Zabrocki | Nov 1989 | A |
4885119 | Mueller et al. | Dec 1989 | A |
4902558 | Henricksen | Feb 1990 | A |
4910085 | Raniere et al. | Mar 1990 | A |
4911963 | Lustig et al. | Mar 1990 | A |
4911979 | Nishimoto et al. | Mar 1990 | A |
4915893 | Gogolewski et al. | Apr 1990 | A |
4917925 | Loretti et al. | Apr 1990 | A |
4923470 | Dumican | May 1990 | A |
4929479 | Shishido et al. | May 1990 | A |
4931520 | Yamanashi et al. | Jun 1990 | A |
4937139 | Genske et al. | Jun 1990 | A |
4948643 | Mueller | Aug 1990 | A |
4950515 | Mason et al. | Aug 1990 | A |
4957966 | Nishio et al. | Sep 1990 | A |
4957967 | Mizuno et al. | Sep 1990 | A |
RE33376 | Gibbons et al. | Oct 1990 | E |
4963426 | Nishimoto et al. | Oct 1990 | A |
4966795 | Genske et al. | Oct 1990 | A |
4971864 | McCord | Nov 1990 | A |
4975207 | Lee | Dec 1990 | A |
4977213 | Giroud-Abel et al. | Dec 1990 | A |
4983432 | Bissot | Jan 1991 | A |
4992511 | Yamamoto et al. | Feb 1991 | A |
4996054 | Pietsch et al. | Feb 1991 | A |
4999254 | Ofstein | Mar 1991 | A |
5003019 | Ishimaru et al. | Mar 1991 | A |
5004647 | Shah | Apr 1991 | A |
5006114 | Rogers et al. | Apr 1991 | A |
5006601 | Lutz et al. | Apr 1991 | A |
5008356 | Ishimaru et al. | Apr 1991 | A |
5017652 | Abe et al. | May 1991 | A |
5034457 | Serini et al. | Jul 1991 | A |
5034458 | Serini et al. | Jul 1991 | A |
5039565 | Deyrup | Aug 1991 | A |
5040583 | Lin et al. | Aug 1991 | A |
5049449 | Ofstein | Sep 1991 | A |
5053259 | Vicik | Oct 1991 | A |
5053457 | Lee | Oct 1991 | A |
5061771 | Oshima et al. | Oct 1991 | A |
5066290 | Measells et al. | Nov 1991 | A |
5070143 | Pucci et al. | Dec 1991 | A |
5071686 | Genske et al. | Dec 1991 | A |
5071911 | Furuta et al. | Dec 1991 | A |
5071912 | Furuta et al. | Dec 1991 | A |
5075376 | Furuta et al. | Dec 1991 | A |
5077109 | Lustig et al. | Dec 1991 | A |
5079295 | Furuta et al. | Jan 1992 | A |
RE33832 | Yoshimura et al. | Feb 1992 | E |
5085649 | Flynn | Feb 1992 | A |
5085816 | McCord | Feb 1992 | A |
5087677 | Brekner et al. | Feb 1992 | A |
5093164 | Bauer et al. | Mar 1992 | A |
5093194 | Touhsaent et al. | Mar 1992 | A |
5094921 | Itamura et al. | Mar 1992 | A |
5108807 | Tucker | Apr 1992 | A |
5108844 | Blemberg et al. | Apr 1992 | A |
5110642 | Genske | May 1992 | A |
5116906 | Mizuno et al. | May 1992 | A |
5126198 | Schinkel et al. | Jun 1992 | A |
5127904 | Loo et al. | Jul 1992 | A |
5129894 | Sommermeyer et al. | Jul 1992 | A |
5132149 | Kotani et al. | Jul 1992 | A |
5132363 | Furuta et al. | Jul 1992 | A |
5135785 | Millon | Aug 1992 | A |
5137763 | Bauer et al. | Aug 1992 | A |
5139831 | Mueller | Aug 1992 | A |
5141795 | Kai et al. | Aug 1992 | A |
5143570 | Freedman | Sep 1992 | A |
5145731 | Lund et al. | Sep 1992 | A |
5149739 | Lee | Sep 1992 | A |
5154979 | Kerschbaumer et al. | Oct 1992 | A |
5156921 | Lin et al. | Oct 1992 | A |
5159004 | Furuta et al. | Oct 1992 | A |
5164258 | Shida et al. | Nov 1992 | A |
5164267 | D'Heur et al. | Nov 1992 | A |
5165988 | Schaefer | Nov 1992 | A |
5169697 | Langley et al. | Dec 1992 | A |
5171640 | Wirth | Dec 1992 | A |
5176634 | Smith et al. | Jan 1993 | A |
5176956 | Jevne et al. | Jan 1993 | A |
5183706 | Bekele | Feb 1993 | A |
5185189 | Stenger et al. | Feb 1993 | A |
5186782 | Freedman | Feb 1993 | A |
5189091 | Laughner | Feb 1993 | A |
5194316 | Horner et al. | Mar 1993 | A |
5196254 | Akiyama | Mar 1993 | A |
5206290 | Mizuno et al. | Apr 1993 | A |
5207983 | Liebert et al. | May 1993 | A |
5208082 | Chou | May 1993 | A |
5208094 | Sun | May 1993 | A |
5212238 | Schelbelhoffer et al. | May 1993 | A |
5216062 | Lausberg et al. | Jun 1993 | A |
5218048 | Abe et al. | Jun 1993 | A |
5218049 | Yamamoto et al. | Jun 1993 | A |
5230934 | Sakano et al. | Jul 1993 | A |
5230935 | Delimoy et al. | Jul 1993 | A |
5232754 | Waugh | Aug 1993 | A |
5234731 | Ferguson | Aug 1993 | A |
5234903 | Nho et al. | Aug 1993 | A |
5238997 | Bauer et al. | Aug 1993 | A |
5244971 | Dekoninck | Sep 1993 | A |
5258230 | LaFleur et al. | Nov 1993 | A |
5272235 | Wakatsuru et al. | Dec 1993 | A |
5278231 | Chundury | Jan 1994 | A |
RE34537 | Deyrup | Feb 1994 | E |
RE34546 | Deyrup | Feb 1994 | E |
5283128 | Wilhoit | Feb 1994 | A |
5288531 | Falla et al. | Feb 1994 | A |
5288560 | Sudo et al. | Feb 1994 | A |
5288799 | Schmid et al. | Feb 1994 | A |
5290856 | Okamoto et al. | Mar 1994 | A |
5292590 | Lin et al. | Mar 1994 | A |
5300354 | Harita et al. | Apr 1994 | A |
5306542 | Bayer | Apr 1994 | A |
5312867 | Mitsuno et al. | May 1994 | A |
5317059 | Chundury et al. | May 1994 | A |
5318829 | Tada et al. | Jun 1994 | A |
5331057 | Brekner et al. | Jul 1994 | A |
5342886 | Glotin et al. | Aug 1994 | A |
5346732 | Lai et al. | Sep 1994 | A |
5348771 | Lee et al. | Sep 1994 | A |
5348794 | Takahashi et al. | Sep 1994 | A |
5352773 | Kandler et al. | Oct 1994 | A |
5356676 | von Widdern et al. | Oct 1994 | A |
5356709 | Woo et al. | Oct 1994 | A |
5360670 | Yonezu et al. | Nov 1994 | A |
5362532 | Famili et al. | Nov 1994 | A |
5370937 | Lee et al. | Dec 1994 | A |
5371141 | Gelles et al. | Dec 1994 | A |
5372669 | Freedman | Dec 1994 | A |
5372880 | Lee et al. | Dec 1994 | A |
5374459 | Mumpower et al. | Dec 1994 | A |
5378543 | Murata et al. | Jan 1995 | A |
5378800 | Mok et al. | Jan 1995 | A |
5380586 | Knoerzer et al. | Jan 1995 | A |
5382631 | Stehling et al. | Jan 1995 | A |
5387645 | Montag et al. | Feb 1995 | A |
5389448 | Schirmer et al. | Feb 1995 | A |
5407713 | Wilfong et al. | Apr 1995 | A |
5422409 | Brekner et al. | Jun 1995 | A |
5434007 | Yeh | Jul 1995 | A |
5434010 | Smith et al. | Jul 1995 | A |
5457249 | Toshihiro et al. | Oct 1995 | A |
5462807 | Halle et al. | Oct 1995 | A |
5463375 | Bauer | Oct 1995 | A |
5464691 | Gardiner et al. | Nov 1995 | A |
5466498 | Forloni et al. | Nov 1995 | A |
5472792 | Tsurutani et al. | Dec 1995 | A |
5475060 | Brekner et al. | Dec 1995 | A |
5482770 | Bekele | Jan 1996 | A |
5482771 | Shah | Jan 1996 | A |
5487940 | Bianchini et al. | Jan 1996 | A |
5489478 | Audry et al. | Feb 1996 | A |
5491009 | Bekele | Feb 1996 | A |
5491011 | Pezzoli et al. | Feb 1996 | A |
5498677 | Weller et al. | Mar 1996 | A |
RE35285 | Quacquarella et al. | Jun 1996 | E |
5534351 | Pearson et al. | Jul 1996 | A |
5534606 | Bennett et al. | Jul 1996 | A |
5547764 | Blais et al. | Aug 1996 | A |
5547765 | Degrassi et al. | Aug 1996 | A |
5552002 | Farrell et al. | Sep 1996 | A |
5552212 | Knoerzer | Sep 1996 | A |
5552504 | Bennett et al. | Sep 1996 | A |
5558930 | DiPoto | Sep 1996 | A |
5559176 | Namba et al. | Sep 1996 | A |
5562996 | Kuriu et al. | Oct 1996 | A |
5583192 | Bennett et al. | Dec 1996 | A |
5601889 | Chundury et al. | Feb 1997 | A |
5604042 | Bianchini et al. | Feb 1997 | A |
5604043 | Ahlgren | Feb 1997 | A |
5610253 | Hatke et al. | Mar 1997 | A |
5618599 | Nulman et al. | Apr 1997 | A |
5620425 | Hefferman et al. | Apr 1997 | A |
5620758 | Babrowicz | Apr 1997 | A |
5628629 | Mitani et al. | May 1997 | A |
5629059 | Desai et al. | May 1997 | A |
5629398 | Okamoto et al. | May 1997 | A |
5637100 | Sudo | Jun 1997 | A |
5637400 | Brekner et al. | Jun 1997 | A |
5645906 | Park et al. | Jul 1997 | A |
5650471 | Abe et al. | Jul 1997 | A |
5686527 | Laurin et al. | Nov 1997 | A |
5693728 | Okamoto et al. | Dec 1997 | A |
5698645 | Weller et al. | Dec 1997 | A |
5723189 | Sudo | Mar 1998 | A |
5733619 | Patel et al. | Mar 1998 | A |
5733991 | Rohrmann et al. | Mar 1998 | A |
5744664 | Brekner et al. | Apr 1998 | A |
5756623 | Kreuder et al. | May 1998 | A |
5788670 | Reinhard et al. | Aug 1998 | A |
5792824 | Natori | Aug 1998 | A |
5795945 | Natori | Aug 1998 | A |
5849843 | Laurin et al. | Dec 1998 | A |
5854347 | Laurin et al. | Dec 1998 | A |
5854349 | Abe et al. | Dec 1998 | A |
5863986 | Herrmann-Schonherr et al. | Jan 1999 | A |
5872201 | Cheung et al. | Feb 1999 | A |
5929031 | Kerwin et al. | Jul 1999 | A |
5935847 | Smith et al. | Aug 1999 | A |
5980495 | Heinz et al. | Nov 1999 | A |
5990254 | Weller et al. | Nov 1999 | A |
5993949 | Rosenbaum et al. | Nov 1999 | A |
5998019 | Rosenbaum et al. | Dec 1999 | A |
6007520 | Sudo | Dec 1999 | A |
6020444 | Riedel et al. | Feb 2000 | A |
6060572 | Gillis et al. | May 2000 | A |
6065270 | Reinhard et al. | May 2000 | A |
6068936 | Pfeiffer et al. | May 2000 | A |
6083587 | Smith et al. | Jul 2000 | A |
6121394 | Sugimoto et al. | Sep 2000 | A |
6136744 | Gillis et al. | Oct 2000 | A |
6147025 | Gillis et al. | Nov 2000 | A |
6149997 | Patel et al. | Nov 2000 | A |
6168862 | Rosenbaum et al. | Jan 2001 | B1 |
6169052 | Brekner et al. | Jan 2001 | B1 |
6213996 | Jepson et al. | Apr 2001 | B1 |
6217568 | Jepson et al. | Apr 2001 | B1 |
6225426 | Gillis et al. | May 2001 | B1 |
6225427 | Burton et al. | May 2001 | B1 |
RE37208 | Winter et al. | Jun 2001 | E |
6255396 | Ding et al. | Jul 2001 | B1 |
6261655 | Rosenbaum et al. | Jul 2001 | B1 |
6271351 | Gawryl et al. | Aug 2001 | B1 |
6288027 | Gawryl et al. | Sep 2001 | B1 |
6344033 | Jepson et al. | Feb 2002 | B1 |
6361843 | Smith et al. | Mar 2002 | B1 |
6399704 | Laurin et al. | Jun 2002 | B1 |
6461696 | Ling et al. | Oct 2002 | B1 |
20020164492 | Nebgen et al. | Nov 2002 | A1 |
Number | Date | Country |
---|---|---|
0 251 904 | Dec 1987 | DE |
41 42 271 | Jun 1993 | DE |
0 092 897 | Feb 1983 | EP |
0 156 464 | Feb 1985 | EP |
0 158 035 | Oct 1985 | EP |
0 230 344 | Jul 1987 | EP |
0 283 164 | Sep 1988 | EP |
0 291 208 | Nov 1988 | EP |
0 291 208 | Nov 1988 | EP |
0 092 897 | Apr 1990 | EP |
0 158 035 | Jan 1991 | EP |
0 216 509 | Sep 1991 | EP |
0 446 505 | Sep 1991 | EP |
0 451 977 | Oct 1991 | EP |
0 465 428 | Jan 1992 | EP |
0 465 681 | Jan 1992 | EP |
0 497 567 | May 1992 | EP |
0 504 808 | Sep 1992 | EP |
0 524 802 | Jan 1993 | EP |
0 561 428 | Sep 1993 | EP |
0 709 105 | Jun 1995 | EP |
0 492 982 | Aug 1995 | EP |
0 430 585 | Jan 1996 | EP |
0 698 487 | Feb 1996 | EP |
0 156 464 | May 1996 | EP |
0 582 355 | May 1996 | EP |
0 203 799 | Jul 1996 | EP |
0 384 694 | Sep 1996 | EP |
0 291 208 | Aug 1997 | EP |
0 790 063 | Aug 1997 | EP |
0 680 401 | Jan 1999 | EP |
0 709 105 | Dec 2001 | EP |
2688511 | Sep 1993 | FR |
2 131 739 | Jun 1984 | GB |
2 177 974 | Feb 1987 | GB |
03-095286 | Apr 1991 | JP |
05-277154 | Oct 1993 | JP |
11-071554 | Mar 1999 | JP |
8300158 | Jan 1983 | WO |
8607010 | Jan 1986 | WO |
9323093 | Nov 1993 | WO |
9708054 | Mar 1997 | WO |
9827926 | Jul 1998 | WO |
9844043 | Oct 1998 | WO |
9915289 | Apr 1999 | WO |
9948990 | Sep 1999 | WO |
Number | Date | Country | |
---|---|---|---|
20020164492 A1 | Nov 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 08153602 | Nov 1993 | US |
Child | 09334957 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 09498674 | Feb 2000 | US |
Child | 10105559 | US | |
Parent | 09334957 | Jun 1999 | US |
Child | 09498674 | US |